BlackBerry Passport Launches a Cancer Genome Browser NantOmics

BlackBerry Passport

BlackBerry Passport launches a cancer genome browser called NantOmics. This is among the fruits of collaboration between Passport maker, Canada-based BlackBerry Limited and NantHealth, a huge cloud-based, data supplier in the healthcare field, which just closed a $320 million funding round. NantOmics is designed to provide doctors, clinicians and treatment providers unprecedented deeper access to the genetic data of patients in real-time.

Following the success of BlackBerry Passport smartphone after some trying times, there is no stopping from BlackBerry from retaining relevance by targeting key industries. The move will give the OEM brand bigger presence in the lucrative world of healthcare, at the same time pushing the hardware, which will come pre-loaded next year with the world’s first secure cancer genome browser.

Medical teams can harness Passport’s large high-resolution screen to access patient genetic data on a secured platform from anywhere. CEO and Founder Patrick Soon-Shiong, M.D., of NantHealth explained that BlackBerry already powers several diagnostic machines which are relied upon by clinicians and tying these machines up with the BlackBerry Passport just makes sense. He said, for the first time, medical staff will be able to check on a tumor genome in real-time, from three billion bases to the single-base level, courtesy of the NantOmics browser’s supercomputing infrastructure.

The BlackBerry Passport launching the NantOmics cancer genome browser utilizes its mobile security infrastructure to power the browser. NantOmics is totally encrypted to be deployed in a Health Insurance Portability and Accountability-secured scene so that medical staff can securely access patient data the moment it is available.

The rising fame of data analytics and the need for patient privacy maintenance in the healthcare field triggered BlackBerry to collaborate with NantHealth. Their tandem illustrates how mobile security can create revolutionary applications to various industries, said BlackBerry CEO John Chen. He added that the reliability, power and security of their devices can be counted on even in life-threatening situations. Their new innovation in the BlackBerry Passport makes the smartphone a deserving part of a physician’s medical kit. The NantOmics browser initially works with BlackBerry’s QNX OS first, but may also support other platforms like iOS and Android in the future.

Though BlackBerry seems to currently enjoy a substantial share in the enterprise phone market, it has been suffering a steady profit decline in the previous years, when iOS and Android started to soar. It is now picking up and seeking to retain a strong hold in some lucrative markets.

The Passport maker continues to explore business options to make up with its past losses. It has penned a three-year deal in June with mobile payment firm EnStream LP, to provide advanced systems of financial transactions between banks and clients. It is in agreement to acquire Secusmart, a high-security text and voice encryption leader. Furthermore, it plans to introduce the BBM Money service to Indonesia. BlackBerry likewise disclosed its collaboration with Samsung for BES12, its cross-platform enterprise mobility management solution, to be brought to Android.

The BES12 EMM solution was announced in February, the very solution which underpins the NantOmics browser that specifically focuses on end-to-end security and encryption. The Canadian OEM first disclosed its partnership with NantHealth in April. NantOmics is the first fruit of the deal, the seemingly initial application, as BlackBerry talked about several innovations to come. The cancer genome browser NantOmics launching in the BlackBerry Passport will be featured at the upcoming Consumer Electronics Show in January. The video below shows how useful the Passport can be with a doctor.

By Judith Aparri


VB News
Business Wire

Photo courtesy by Maurizio Pesce – Flicker License

Leave a Reply

Your email address will not be published.